111 South 11th Street
Room G-301, Bodine Center
Philadelphia, PA 19107
(215) 955-6700
(215) 503-0013 fax
Room G-301, Bodine Center
Philadelphia, PA 19107
(215) 955-6700
(215) 503-0013 fax
Most Recent Peer-reviewed Publications
- β1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1
- Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?
- RTOG 0211: A phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients
- Dietary recommendations during and after cancer treatment: Consistently inconsistent?
- Radiotherapy protocol deviations and clinical outcomes: A meta-analysis of cooperative group clinical trials
- Commissioning and implementation of an implantable dosimeter for radiation therapy
- Impact of a Radiation Oncology Elective on the Careers of Young Physicians: Update on a Prospective Cohort Study
- Systematic review of hypofractionated radiation therapy for prostate cancer
- Predictors of radiation oncology resident research productivity
- Association between metabolic syndrome, diabetes mellitus and prostate cancer risk
- Nutrient restriction and radiation therapy for cancer treatment: When less is more
- A phase i study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas
- NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers
- COX-2 expression and survival in patients with locally advanced cervical cancer treated with chemoradiotherapy and celecoxib : A quantitative immunohistochemical analysis of RTOG C0128
- On the merits and limitations of whole-brain radiation therapy
- Fractionated stereotactic radiation therapy improves cranial neuropathies in patients with skull base meningiomas: A retrospective cohort study
- Salvage radiotherapy for prostate cancer: Finding a way forward using radiobiological modeling
- Dual roles of PARP-1 promote cancer growth and progression
- Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects.
- Radiotherapy improves survival in unresected stage I-III bronchoalveolar carcinoma